Overview

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Status:
RECRUITING
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.
Phase:
PHASE3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
orforglipron